The 1st Affiliated Hospital of Guangxi Medical University
Welcome,         Profile    Billing    Logout  
 7 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hu, Xiaohua
NCT02633176: Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma

Recruiting
3
120
RoW
Cetuximab, Erbitux, Cisplatin, Docetaxel, Taxotere, Capecitabine, Xeloda, Radiotherapy
Sun Yat-sen University, Chinese Southwest Oncology Group
Nasopharyngeal Carcinoma
01/23
 
NCT05768503: Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC

Recruiting
3
176
RoW
Experimental drug, CAP, Control Rx, FOLFIRI+BEV
Sun Yat-sen University
Metastatic Microsatellite-stable Colorectal Cancer
01/26
01/27
NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers

Recruiting
2
100
RoW
Toripalimab, Tuoyi
Shanghai Junshi Bioscience Co., Ltd.
Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy
12/22
03/23
NCT04000737: YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

Recruiting
2
125
US, RoW
YIV-906+Sorafenib, Placebo+Sorafenib
Yiviva Inc.
Advanced Hepatocellular Carcinoma
12/23
05/24
NCT04322006: A Phase I/II Study of TJ004309 for Advanced Solid Tumor

Active, not recruiting
1/2
376
RoW
TJ004309, Toripalimab
TJ Biopharma Co., Ltd.
Advanced Solid Tumor
12/24
12/24

Download Options